Insights

Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operations under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

May 15, 2017

Executive Interview - PCT: Manufacturing the Future of Cell Therapies

In an interview published in the May 2017 issue of Drug Development & Delivery, PCT President Robert Preti, PhD, discusses PCT’s founding, differentiators, growth, ...

May 10, 2017

Understanding Today’s CAR-T Cell Therapy Manufacturing Challenges

CAR-T cell therapy presents numerous challenges for cell therapy developers who are looking to move towards commercialization. The move from development to commercial ...

April 25, 2017

Planning Ahead: Selecting Appropriate Source Materials for Cell-Based Therapy Manufacturing

Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, ...

April 18, 2017

Impact of Apheresis Collection Quality on Manufacturing of Cell Therapeutics

One of the most critical first steps in the development of many cell therapies is having optimized apheresis collections. Starting with variable or low-quality apheresis ...

March 23, 2017

Moving Toward Controlled, Non-Classified Space For Cell Therapies

Despite the advances the cell therapy industry has made in recent years, commercially viable manufacturing continues to be an elusive challenge. In order for the cell ...

March 7, 2017

Safety First: Shipping Cell Therapy Materials

Cell therapies are at the forefront of saving lives – providing critical treatments to patients who might otherwise have very few viable options. Because these therapies ...

February 16, 2017

Challenges and Optimization of Apheresis Collection

On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as ...

November 15, 2016

Current and Future Scale-Out Needs in Cell Therapy Manufacturing

The following is an excerpt from a paper originally published online in the journal Cytotherapy on October 26, 2016, entitled, “Bioreactors for cell therapies: Current ...

October 28, 2016

Look Before You Leap – Planning Ahead in Cell Therapy Manufacturing

The following is an excerpt of an article I wrote that was originally published in the October 2016 issue of The Medicine Maker. Some companies still fail to look beyond ...

Previous All Posts Next